Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Lung Neoplasms 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Advanced Malignancies 2Solid Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1

Interventions

Imatinib Mesylate 26Sunitinib 22nilotinib 12ripretinib 11regorafenib 7avapritinib 7tanespimycin 2pexidartinib 2masitinib 2famitinib 2Midazolam 2IDRX-42 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2umbralisib 1trastuzumab deruxtecan 1trametinib 1tinostamustine 1spartalizumab 1ribociclib 1repaglinide 1ponatinib 1perifosine 1pembrolizumab 1olverembatinib 1olaratumab 1motesanib diphosphate 1dabrafenib 1cediranib 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Stromal Tumors × tanespimycin × Clear all
NCT00688766 2012-12-11

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Infinity Pharmaceuticals, Inc.

Phase 3 Terminated
47 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00276302 2011-01-06

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Infinity Pharmaceuticals, Inc.

Phase 1 Completed
63 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡